AAPL308.63+14.25 (+4.84%) ▲|ABBV261.07+10.01 (+3.99%) ▲|ABT95.40+3.22 (+3.49%) ▲|ACN137.35+6.22 (+4.74%) ▲|ADBE219.72+8.74 (+4.14%) ▲|AMAT603.04-47.87 (-7.35%) ▼|AMD517.82-23.06 (-4.26%) ▼|AMGN374.15+12.82 (+3.55%) ▲|AMT166.03-0.05 (-0.03%) ▼|AMZN242.67+0.97 (+0.40%) ▲|AVGO360.45-8.89 (-2.41%) ▼|AXP351.96+4.91 (+1.41%) ▲|BA226.49+7.91 (+3.62%) ▲|BAC58.73+0.37 (+0.63%) ▲|BKNG184.56+1.92 (+1.05%) ▲|BLK995.73+15.35 (+1.57%) ▲|BMY58.13+2.32 (+4.16%) ▲|BNY146.62+0.60 (+0.41%) ▲|BRK-B507.78+8.04 (+1.61%) ▲|C139.97-0.16 (-0.11%) ▼|CAT963.53-27.88 (-2.81%) ▼|CL95.13+2.37 (+2.56%) ▲|CMCSA23.79+0.06 (+0.25%) ▲|COF205.12+0.30 (+0.15%) ▲|COP104.73+1.51 (+1.46%) ▲|COST951.67+27.00 (+2.92%) ▲|CRM166.11+2.88 (+1.76%) ▲|CSCO112.69-4.32 (-3.69%) ▼|CVS104.72-0.09 (-0.09%) ▼|CVX169.20+3.51 (+2.12%) ▲|DE621.27-6.36 (-1.01%) ▼|DHR197.93+4.21 (+2.17%) ▲|DIS99.50+3.79 (+3.96%) ▲|DUK129.60+3.83 (+3.05%) ▲|EMR139.05-0.47 (-0.34%) ▼|FDX313.00-0.89 (-0.28%) ▼|GD373.54+12.27 (+3.40%) ▲|GE377.52+2.58 (+0.69%) ▲|GEV1,113.11-21.24 (-1.87%) ▼|GILD131.27+5.30 (+4.21%) ▲|GM76.00+0.48 (+0.64%) ▲|GOOG356.18-1.71 (-0.48%) ▼|GOOGL359.91-1.30 (-0.36%) ▼|GS1,021.00+1.39 (+0.14%) ▲|HD357.90+7.06 (+2.01%) ▲|HON229.86+8.11 (+3.66%) ▲|IBM289.52+3.27 (+1.14%) ▲|INTC120.35-6.67 (-5.25%) ▼|INTU275.35+8.27 (+3.10%) ▲|ISRG426.01+23.63 (+5.87%) ▲|JNJ263.04+9.06 (+3.57%) ▲|JPM334.47+0.40 (+0.12%) ▲|KO84.14+2.85 (+3.51%) ▲|LIN546.64+13.09 (+2.45%) ▲|LLY1,213.91+22.17 (+1.86%) ▲|LMT545.91+24.09 (+4.62%) ▲|LOW227.50+5.58 (+2.51%) ▲|LRCX351.41-39.85 (-10.19%) ▼|MA539.39+16.95 (+3.24%) ▲|MCD280.63+11.20 (+4.16%) ▲|MDLZ60.91+1.56 (+2.63%) ▲|MDT83.19+3.99 (+5.04%) ▲|META582.90-30.01 (-4.90%) ▼|MMM160.44+0.48 (+0.30%) ▲|MO72.71+1.17 (+1.64%) ▲|MRK129.56+4.19 (+3.34%) ▲|MS213.93+2.07 (+0.98%) ▲|MSFT390.49+6.21 (+1.62%) ▲|MU975.56-56.72 (-5.49%) ▼|NEE88.34+1.97 (+2.28%) ▲|NFLX77.65+3.46 (+4.66%) ▲|NKE44.09+1.03 (+2.39%) ▲|NOW106.32+0.52 (+0.49%) ▲|NVDA194.83-2.75 (-1.39%) ▼|ORCL140.27-2.23 (-1.56%) ▼|PEP144.22+3.06 (+2.17%) ▲|PFE24.32+0.44 (+1.84%) ▲|PG151.41+3.98 (+2.70%) ▲|PLTR129.30+3.57 (+2.84%) ▲|PM182.27+4.58 (+2.58%) ▲|QCOM176.25-5.67 (-3.12%) ▼|RTX199.25+7.47 (+3.90%) ▲|SBUX104.27+0.88 (+0.85%) ▲|SCHW97.00+1.22 (+1.27%) ▲|SO97.98+2.86 (+3.01%) ▲|SPG226.06+3.06 (+1.37%) ▲|T20.58+0.10 (+0.49%) ▲|TMO523.44+10.11 (+1.97%) ▲|TMUS177.52+4.46 (+2.58%) ▲|TSLA393.45-31.85 (-7.49%) ▼|TXN293.08-5.33 (-1.79%) ▼|UBER74.43+1.77 (+2.44%) ▲|UNH425.36-1.18 (-0.28%) ▼|UNP282.25+4.52 (+1.63%) ▲|UPS110.66+1.12 (+1.02%) ▲|USB61.73-0.23 (-0.37%) ▼|V362.13+11.05 (+3.15%) ▲|VZ42.56+0.57 (+1.36%) ▲|WFC85.51-0.43 (-0.50%) ▼|WMT111.84+3.02 (+2.78%) ▲|XOM137.09+0.81 (+0.59%) ▲|AAPL308.63+14.25 (+4.84%) ▲|ABBV261.07+10.01 (+3.99%) ▲|ABT95.40+3.22 (+3.49%) ▲|ACN137.35+6.22 (+4.74%) ▲|ADBE219.72+8.74 (+4.14%) ▲|AMAT603.04-47.87 (-7.35%) ▼|AMD517.82-23.06 (-4.26%) ▼|AMGN374.15+12.82 (+3.55%) ▲|AMT166.03-0.05 (-0.03%) ▼|AMZN242.67+0.97 (+0.40%) ▲|AVGO360.45-8.89 (-2.41%) ▼|AXP351.96+4.91 (+1.41%) ▲|BA226.49+7.91 (+3.62%) ▲|BAC58.73+0.37 (+0.63%) ▲|BKNG184.56+1.92 (+1.05%) ▲|BLK995.73+15.35 (+1.57%) ▲|BMY58.13+2.32 (+4.16%) ▲|BNY146.62+0.60 (+0.41%) ▲|BRK-B507.78+8.04 (+1.61%) ▲|C139.97-0.16 (-0.11%) ▼|CAT963.53-27.88 (-2.81%) ▼|CL95.13+2.37 (+2.56%) ▲|CMCSA23.79+0.06 (+0.25%) ▲|COF205.12+0.30 (+0.15%) ▲|COP104.73+1.51 (+1.46%) ▲|COST951.67+27.00 (+2.92%) ▲|CRM166.11+2.88 (+1.76%) ▲|CSCO112.69-4.32 (-3.69%) ▼|CVS104.72-0.09 (-0.09%) ▼|CVX169.20+3.51 (+2.12%) ▲|DE621.27-6.36 (-1.01%) ▼|DHR197.93+4.21 (+2.17%) ▲|DIS99.50+3.79 (+3.96%) ▲|DUK129.60+3.83 (+3.05%) ▲|EMR139.05-0.47 (-0.34%) ▼|FDX313.00-0.89 (-0.28%) ▼|GD373.54+12.27 (+3.40%) ▲|GE377.52+2.58 (+0.69%) ▲|GEV1,113.11-21.24 (-1.87%) ▼|GILD131.27+5.30 (+4.21%) ▲|GM76.00+0.48 (+0.64%) ▲|GOOG356.18-1.71 (-0.48%) ▼|GOOGL359.91-1.30 (-0.36%) ▼|GS1,021.00+1.39 (+0.14%) ▲|HD357.90+7.06 (+2.01%) ▲|HON229.86+8.11 (+3.66%) ▲|IBM289.52+3.27 (+1.14%) ▲|INTC120.35-6.67 (-5.25%) ▼|INTU275.35+8.27 (+3.10%) ▲|ISRG426.01+23.63 (+5.87%) ▲|JNJ263.04+9.06 (+3.57%) ▲|JPM334.47+0.40 (+0.12%) ▲|KO84.14+2.85 (+3.51%) ▲|LIN546.64+13.09 (+2.45%) ▲|LLY1,213.91+22.17 (+1.86%) ▲|LMT545.91+24.09 (+4.62%) ▲|LOW227.50+5.58 (+2.51%) ▲|LRCX351.41-39.85 (-10.19%) ▼|MA539.39+16.95 (+3.24%) ▲|MCD280.63+11.20 (+4.16%) ▲|MDLZ60.91+1.56 (+2.63%) ▲|MDT83.19+3.99 (+5.04%) ▲|META582.90-30.01 (-4.90%) ▼|MMM160.44+0.48 (+0.30%) ▲|MO72.71+1.17 (+1.64%) ▲|MRK129.56+4.19 (+3.34%) ▲|MS213.93+2.07 (+0.98%) ▲|MSFT390.49+6.21 (+1.62%) ▲|MU975.56-56.72 (-5.49%) ▼|NEE88.34+1.97 (+2.28%) ▲|NFLX77.65+3.46 (+4.66%) ▲|NKE44.09+1.03 (+2.39%) ▲|NOW106.32+0.52 (+0.49%) ▲|NVDA194.83-2.75 (-1.39%) ▼|ORCL140.27-2.23 (-1.56%) ▼|PEP144.22+3.06 (+2.17%) ▲|PFE24.32+0.44 (+1.84%) ▲|PG151.41+3.98 (+2.70%) ▲|PLTR129.30+3.57 (+2.84%) ▲|PM182.27+4.58 (+2.58%) ▲|QCOM176.25-5.67 (-3.12%) ▼|RTX199.25+7.47 (+3.90%) ▲|SBUX104.27+0.88 (+0.85%) ▲|SCHW97.00+1.22 (+1.27%) ▲|SO97.98+2.86 (+3.01%) ▲|SPG226.06+3.06 (+1.37%) ▲|T20.58+0.10 (+0.49%) ▲|TMO523.44+10.11 (+1.97%) ▲|TMUS177.52+4.46 (+2.58%) ▲|TSLA393.45-31.85 (-7.49%) ▼|TXN293.08-5.33 (-1.79%) ▼|UBER74.43+1.77 (+2.44%) ▲|UNH425.36-1.18 (-0.28%) ▼|UNP282.25+4.52 (+1.63%) ▲|UPS110.66+1.12 (+1.02%) ▲|USB61.73-0.23 (-0.37%) ▼|V362.13+11.05 (+3.15%) ▲|VZ42.56+0.57 (+1.36%) ▲|WFC85.51-0.43 (-0.50%) ▼|WMT111.84+3.02 (+2.78%) ▲|XOM137.09+0.81 (+0.59%) ▲|
27.7 C
New York
Sunday, July 5, 2026

Tag: stage

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET.

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units covering 30,000 shares of its common stock to Jim Hagen, the Company’s Senior Vice President – Strategic Commercial Operations, with a grant date of June 2, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Mr. Hagen’s employment compensation and were granted as an inducement material to his acceptance of employment with TELA Bio.

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 a.m. Eastern time.

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis’ common stock to nine newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

XOVR ETF Adds Anduril, Joining SpaceX to Offer Pre-IPO Access

XOVR ETF Adds Anduril to Crossover Fund. Joins SpaceX and Klarna as Private Equity Holdings in ETF that Holds 85%+ of Entrepreneur 30 Total Return Index

Seeds of Fortune Inc. and Marsai Martin Join Forces to Empower 10,000 Young Women Through Financial Education and Wealth-Building

NEW YORK, June 6, 2025 /PRNewswire/ -- Seeds of Fortune Inc., a nonprofit dedicated to the economic empowerment of youth, is proud to announce an...

Kwanza Jones Introduces Inaugural Innovator Award Honoring Teyana Taylor at Historic Apollo Spring Benefit

This year, SUPERCHARGED® CEO Kwanza Jones returns as an Apollo Board Member and Premier Sponsor through her and her husband's Kwanza Jones & José...

The Peach Cobbler Factory is coming to DFW International Airport with Two Locations

FT. LAUDERDALE, Fla., June 6, 2025 /PRNewswire/ -- The Peach Cobbler Factory, renowned for its irresistible Southern-inspired desserts, is thrilled to announce it will...

Analysts See ‘Historic Dislocation’ Between Gold Prices and Miner Valuations

USA News Group News Commentary Issued on behalf of RUA GOLD Inc. VANCOUVER, BC, June 6, 2025 /PRNewswire/ -- USA News Group News Commentary – Gold...

EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR[1]

SYDNEY, June 7, 2025 /PRNewswire/ -- New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStage